Hempire Pharma (Japan), a subsidiary of Hempire Technology Group, has launched エンディミン^®, for patients with Alzheimer's disease and Parkinson's disease. エンディミン^® is developed based on the company's patented neurodegenerative diseases and uses a specific cannabinoid composition as the main ingredient. 

According to patent documents, the cannabinoid composition used in エンディミン^® can directly act on brain neurons to achieve neuroprotection and neuroregeneration, thereby solving symptoms related to Parkinson's disease and Alzheimer's disease.

The patented composition used in this product has been verified by Professor Dai Ping, an authoritative Japanese expert in the field of cell regeneration, and has been developed and produced in Japan. Currently, this product is first available in the form of an oil. Hempire Pharma (Japan) is jointly promoting clinical trials of relevant compositions in Japan with a team of professors with high industry reputation.

In early December this year, Japan officially revised a ground-breaking bill. So far, the medical use of cannabis has been legal in Japan. This will greatly promote Japan’s research and development capabilities and scientific research transformation capabilities in the field of medical cannabis. Japan will become another rising medical cannabis market in addition to the United States, Canada and some European countries. Hempire Technology Group is proud to be a member of the industry and contribute to the industry as well as patients and families in need.